Need for risk stratification in treatment of patients with autoimmune hepatitis

We read with keen interest the study by Plagiannakos CG and colleagues1, which explored the association between sustained elevated aminotransferase levels and long-term outcomes in patients with autoimmune hepatitis (AIH)1. This large multicenter cohort study provides robust evidence for good treatment response and clinical event-free survival in AIH patients. While previous research suggested that lower serum immunoglobin G (IgG) levels could predict the biochemical response of AIH patients2, Plagiannakos CG et al.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research